| Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down |
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates. |
zacks.com |
2025-05-08 15:45:38 |
Czytaj oryginał (ang.) |
| Why Apellis Pharmaceuticals Wilted on Wednesday |
A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 (^GSPC 0.43%) closed in the black with a 0.4% gain. |
fool.com |
2025-05-07 22:09:10 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript |
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and Chief Executive Officer Tim Sullivan – Chief Financial Officer David Acheson – Executive Vice President-Commercial Caroline Baumal – Chief Medical Officer Conference Call Participants Jon Miller – Evercore Tazeen Ahmad – Bank of America Securities Anupam Rama – JPM Steve Seedhouse – Cantor Colleen Kusy – Baird Eliana Merle – UBS Annabel Samimy – Stifel Biren Amin – Piper Sandler Yigal Nochomovitz – Citigroup Douglas Tsao – H.C. Wainwright Lachlan Hanbury-Brown – William Blair Ryan Deschner – Raymond James Judah Frommer – Morgan Stanley Greg Harrison – Scotiabank Graig Suvannavejh – Mizuho Securities Lisa Walter – RBC Operator Hello, everyone. |
seekingalpha.com |
2025-05-07 17:18:48 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-07 14:35:37 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates |
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2025-05-07 13:10:44 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results |
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2025 financial results and business highlights. |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals to Present at Upcoming Investor Conferences |
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m. |
globenewswire.com |
2025-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results |
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. |
globenewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release |
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:06:43 |
Czytaj oryginał (ang.) |
| Apellis Announces Craig Wheeler to Join the Board of Directors |
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. |
globenewswire.com |
2025-04-21 11:00:00 |
Czytaj oryginał (ang.) |
| APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag |
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway. |
zacks.com |
2025-04-02 14:15:42 |
Czytaj oryginał (ang.) |
| FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals |
The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). |
benzinga.com |
2025-04-01 18:11:58 |
Czytaj oryginał (ang.) |
| Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN |
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases. |
globenewswire.com |
2025-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals: A Mixed Bag |
Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand. |
seekingalpha.com |
2025-03-05 16:06:03 |
Czytaj oryginał (ang.) |
| Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst |
Last week, Apellis Pharmaceuticals Inc APLS reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million. |
benzinga.com |
2025-03-05 16:04:46 |
Czytaj oryginał (ang.) |
| Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues |
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre. |
zacks.com |
2025-03-03 14:01:14 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript |
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Cedric Francois - Co-Founder and CEO Caroline Baumal - Chief Medical Officer David Acheson - EVP, Commercial Tim Sullivan - CFO Meredith Kaya - SVP, IR and Strategic Finance Conference Call Participants Jon Miller - Evercore ISI Tazeen Ahmad - Bank of America Securities Malcolm Kuno - J.P. Morgan Salveen Richter - Goldman Sachs Yigal Nochomovitz - Citigroup Colleen Cusi - Robert W. |
seekingalpha.com |
2025-03-02 04:08:44 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-28 12:30:33 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates |
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.73 per share a year ago. |
zacks.com |
2025-02-28 11:15:21 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results |
WALTHAM, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2024 financial results and business highlights. |
globenewswire.com |
2025-02-28 09:05:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference |
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. |
globenewswire.com |
2025-02-24 09:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-21 13:00:35 |
Czytaj oryginał (ang.) |
| Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN |
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments. |
globenewswire.com |
2025-02-20 04:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results |
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. |
globenewswire.com |
2025-02-14 09:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the company approved the grant of equity awards to three new employees with a grant date of February 3, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-04 18:05:00 |
Czytaj oryginał (ang.) |
| Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA) |
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an intact fovea and when central vision is threatened by GA lesion growth. SYFOVRE is the first and only approved treatment for GA in Australia. |
globenewswire.com |
2025-01-27 18:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect |
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accessnewswire.com |
2025-01-21 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out |
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accessnewswire.com |
2025-01-20 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accessnewswire.com |
2025-01-19 12:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accessnewswire.com |
2025-01-17 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accessnewswire.com |
2025-01-16 12:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accesswire.com |
2025-01-15 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect |
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accesswire.com |
2025-01-14 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation |
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accesswire.com |
2025-01-13 12:00:00 |
Czytaj oryginał (ang.) |
| Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference |
WALTHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues for the fourth quarter and the full year 2024 for SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH) as well as its strategic priorities for continued growth. |
globenewswire.com |
2025-01-13 11:00:00 |
Czytaj oryginał (ang.) |
| APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm |
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accesswire.com |
2025-01-12 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect |
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accesswire.com |
2025-01-10 12:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation |
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accesswire.com |
2025-01-09 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS. |
accesswire.com |
2025-01-08 12:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-07 18:05:00 |
Czytaj oryginał (ang.) |
| APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of long-term stockholders following a class action complaint that was filed against Apellis on August 2, 2023 with a Class Period from January 28, 2021 to July 28, 2023. Our investigation concerns whether the board of directors of Apellis have breached their fiduciary duties to the company. |
globenewswire.com |
2024-12-23 23:00:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of December 2, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-06 18:05:00 |
Czytaj oryginał (ang.) |
| Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report? |
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-05 14:36:16 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals to Present at Upcoming Investor Conferences |
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences: |
globenewswire.com |
2024-11-27 09:00:00 |
Czytaj oryginał (ang.) |
| Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y |
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year. |
zacks.com |
2024-11-06 14:35:26 |
Czytaj oryginał (ang.) |
| Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday |
Sales of the company's top commercialized product didn't meet expectations. |
fool.com |
2024-11-05 18:47:37 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript |
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Meredith Kaya - Senior Vice President of Investor Relations and Strategic Finance Cedric Francois - Co-Founder and Chief Executive Officer Adam Townsend - Chief Operating Officer Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Salveen Richter - Goldman Sachs Yigal Nochomovitz - Citigroup Nicholas Econom - Raymond James Phil Nadeau - TD Cowen Katherine Wang - Jefferies Ellie Merle - UBS Annabel Samimy - Stifel Douglas Tsao - H.C. Wainwright Lachlan Hanbury-Brown - William Blair Derek Archila - Wells Fargo Biren Amin - Piper Sandler Lisa Walter - RBC Greg Harrison - Scotiabank Graig Suvannavejh - Mizuho Securities Laura Chico - Wedbush Securities Operator Good morning, ladies and gentlemen. |
seekingalpha.com |
2024-11-05 17:14:09 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-11-05 12:36:24 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates |
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago. |
zacks.com |
2024-11-05 11:21:09 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results |
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2024 financial results and business highlights. |
globenewswire.com |
2024-11-05 09:05:00 |
Czytaj oryginał (ang.) |
| Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know |
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-29 13:06:39 |
Czytaj oryginał (ang.) |
| 1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst |
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. |
fool.com |
2024-10-29 07:51:00 |
Czytaj oryginał (ang.) |
| Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN |
WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American Society of Nephrology (ASN) Kidney Week. The results highlighted the strength of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, debilitating kidney diseases. |
globenewswire.com |
2024-10-26 18:00:00 |
Czytaj oryginał (ang.) |
| Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch |
William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. APLS and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of two therapies: Empaveli (systemic pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and Syfovre (intravitreal pegcetacoplan) for geographic atrophy secondary to age-related macular degeneration. |
benzinga.com |
2024-10-16 18:56:59 |
Czytaj oryginał (ang.) |
| Prediction: This Will Be the Best-Performing Growth Stock Over the Next 5 Years |
24/7 Wall St. Insights Here are some candidates to be the best-performing growth stock over the next five years. |
247wallst.com |
2024-10-09 13:15:37 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of October 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-10-04 20:05:00 |
Czytaj oryginał (ang.) |
| Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade) |
Apellis Pharmaceuticals' Syfovre, despite initial safety concerns, shows strong revenue growth and is nearing profitability, making it a high-risk, high-reward investment. Syfovre's adjusted safety profile and bimonthly dosing offer advantages over Astellas' Izervay, though continued vigilance for retinal vasculitis is necessary. The Company's financial health is solid, with sufficient cash and assets to cover liabilities and fund operations until positive cash flow is achieved. |
seekingalpha.com |
2024-10-04 09:31:11 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm |
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) breached their fiduciary duties to shareholders. |
globenewswire.com |
2024-10-03 16:16:00 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion |
Despite the CHMP's negative opinion on pegcetacoplan for GA in Europe, Apellis still has significant growth potential in the U.S. and other markets. The U.S. market remains crucial for Apellis, with SYFOVRE being the first approved GA treatment, expected to capture a large market share. Apellis' strong cash position and promising pipeline, including potential approvals for C3G and IC-MPGN, provide a buffer against the European setback. |
seekingalpha.com |
2024-10-01 17:15:38 |
Czytaj oryginał (ang.) |
| Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day |
WALTHAM, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the UBS Virtual Ophthalmology Day on Wednesday, October 2, 2024, at 8:30 a.m. ET. |
globenewswire.com |
2024-09-25 11:00:00 |
Czytaj oryginał (ang.) |